CFD RESEARCH CORPORATION — Department of Defense STTR Phase I: AF19A-T002

Description

hazardous chemicals such as JP8, chromium, and byproducts of led-free frangible ammunition and to hazardous environments. Of the many dangers Airmen face, the hypoxia-like unexplained physiological events pilots face are some of the most dangerous and elusive. Current wearable sensors cannot decouple complex, interdependent in vivo response. We propose to develop (design, fabricate, test, and demonstrate) bioprinted organoids that recapitulates human-level architectures, and has integrated optical and impedance sensors that can monitor physiological markers. During Phase I, we will demonstrate proof-of-concept organoids and electrical sensors for functional, cell-based detection of hypoxia in a vascular and neural model. Organoid viability will be evaluated and functionality will be evaluated both with designed sensors and standard analytic techniques for both normoxia and hypoxia. In Phase II, organoids will be further developed. A small, portable bioreactor will also be developed integrating the organoids and sensors with means for environmental exposure while maintaining the organoids at otherwise physiological conditions. The developed platform will be validated in the laboratory and in potentially hazardous environments and commercialization efforts will be started